David Hakimian

Dr. David Hakimian

Hematology | Oncology
8915 W Golf Rd 4th Fl, 
Niles, IL 
On Staff At
8915 W Golf Rd 4th Fl, 
Niles, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Hakimian is a Hematologist and an Oncologist in Niles, Illinois. Dr. Hakimian is rated as an Experienced provider by MediFind in the treatment of Drug-Induced Thrombocytopenia. His top areas of expertise are Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), Squamous Cell Lung Carcinoma, Lung Adenocarcinoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 25 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
Advocate Lutheran General Hospital, Internal Medicine
Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Board Certifications
American Board Of Internal Medicine, Hematology
Fellowships
Northwestern University, Hematology/Oncology
Hospital Affiliations
Advocate Lutheran General Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Illinois Cancer Specialists
8915 W Golf Rd 4th Fl, Niles, IL 60714

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Biological, Drug
Study Drugs: Niraparib, Pembrolizumab
Study Phase: Phase 3
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug
Study Drugs: VS-6766, VS-6766+Defactinib
Study Phase: Phase 2
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: November 04, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

25 Total Publications

Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network's MYLUNG Consortium.
Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network's MYLUNG Consortium.
Journal: Journal of the advanced practitioner in oncology
Published: January 13, 2025
Similar Doctors
Advanced in Drug-Induced Thrombocytopenia
Dr. Geeta Kurra
Hematology Oncology | Hematology | Oncology
Advanced in Drug-Induced Thrombocytopenia
Dr. Geeta Kurra
Hematology Oncology | Hematology | Oncology

Chesterton Physical Therapy Inc

425 Sand Creek Dr, Suite C, 
Chesterton, IN 
 (49.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Geeta Kurra is a Hematologist Oncology specialist and a Hematologist in Chesterton, Indiana. Dr. Kurra is rated as a Distinguished provider by MediFind in the treatment of Drug-Induced Thrombocytopenia. Her top areas of expertise are Iron Deficiency Anemia, Colorectal Cancer, Lynch Syndrome, Bone Marrow Aspiration, and Gastrostomy. Dr. Kurra is currently accepting new patients.

Advanced in Drug-Induced Thrombocytopenia
Dr. Manuel F. Rosado
Hematology Oncology | Hematology | Oncology
Advanced in Drug-Induced Thrombocytopenia
Dr. Manuel F. Rosado
Hematology Oncology | Hematology | Oncology

Oncology Of Northshore Clinic PLLC

2000 Golf Rd, 
Rolling Meadows, IL 
 (10.1 miles away)
847-871-1800
Languages Spoken:
English, Arabic, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Manuel Rosado is a Hematologist Oncology specialist and a Hematologist in Rolling Meadows, Illinois. Dr. Rosado is rated as a Distinguished provider by MediFind in the treatment of Drug-Induced Thrombocytopenia. His top areas of expertise are Deep Vein Thrombosis, Pulmonary Embolism, Familial Colorectal Cancer, Colorectal Cancer, and Bone Marrow Aspiration. Dr. Rosado is currently accepting new patients.

Advanced in Drug-Induced Thrombocytopenia
Dr. Olusola O. Ogundipe
Hematology Oncology | Hematology | Oncology
Advanced in Drug-Induced Thrombocytopenia
Dr. Olusola O. Ogundipe
Hematology Oncology | Hematology | Oncology

Northwest Cancer Centers PC

342 E 109th Ave, Northwest Cancer Ctr, 
Crown Point, IN 
 (48.7 miles away)
219-310-2550
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Olusola Ogundipe is a Hematologist Oncology specialist and a Hematologist in Crown Point, Indiana. Dr. Ogundipe is rated as a Distinguished provider by MediFind in the treatment of Drug-Induced Thrombocytopenia. His top areas of expertise are Myelodysplastic Syndrome (MDS), Leukocytosis, Lung Cancer, and Pleuropulmonary Blastoma. Dr. Ogundipe is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hakimian's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 28 Advanced Conditions
    View All 127 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile